There is supposedly a lot of potential in living bacterial therapeutics (LBT), which are assumed to have a positive influence on various pathophysiological processes from the microbiome. Numerous chronic human diseases, including obesity, non-alcoholic fatty liver disease, type 2 diabetes, atherosclerosis, polycystic ovary syndrome, inflammatory bowel disease, and cancer are targets for LBT in experimental medicine. However, despite the great creativity of experts in the field of synthetic biology, such strategies have so far only worked in model systems that are far removed from the real system, be it mice or humans. It almost always failed because the modified bacteria did not settle in the intestinal microbiome.
Related posts:
Measles Outbreak in Quebec: Importance of Vaccination to Stop the Spread
A famous anchor, who is beautiful, tore her clothes during the live broadcast?.. and falls into the ...
In the video .. Al-Shehri: Do not eat camel meat until you hear this! • Al Marsad newspaper
T cells from colds can protect against coronavirus infection - healing practice
health workers will have an increase of 59% in five installments
Do grapes cause diarrhea? | the concerto
Athletics: Weißhaidinger in Sollentuna second behind steel - athletics
Neighbors suspected that the Egyptian doctor was confining her boyfriend to the practice of vice.. A...